DARVIAS darinaparsin

Drug Class

Organoarsenical compound

Mechanism

Disrupts mitochondrial function and increases intracellular reactive oxygen species (ROS), causing apoptosis in tumor cells.

Approved Indication

Treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

What This Means For Patients

DARVIAS is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• PMDA — Approved (2022) — Sources

Pivotal Clinical Evidence

• Asian Phase 2 Study — Kim et al., Blood Adv 2023 (NCT02653976) — Sources

Sources

• https://www.pmda.go.jp/